NCT07097207View on ClinicalTrials.gov

Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Relapsed/Refractory B-cell Lymphoma
Interventions
COMBINATION_PRODUCT

CAR-T cell

Participants will receive lymphodepleting chemotherapy (FC regimen: Fludarabine + Cyclophosphamide) on Days -5, -4, and -3 relative to the planned CD19/CD20-CAR.p40-T or CD19-CAR.p40-T cell infusion. The CAR-T cell infusion will be administered 72 hours after the completion of the FC chemotherapy.

Trial Locations (1)

518055

RECRUITING

Shenzhen University General Hospital, Shenzhen

All Listed Sponsors
lead

Shenzhen University General Hospital

OTHER